Sumatriptan for Acute Migraine Treatment
Sumatriptan should be used as first-line therapy for moderate to severe acute migraine attacks in combination with an NSAID (or acetaminophen if NSAIDs are contraindicated), with dosing of 50-100 mg orally, 6 mg subcutaneously, or 20 mg intranasally depending on attack severity and patient tolerance. 1
Treatment Algorithm
Step 1: Initial Assessment and Dosing Strategy
Start with oral sumatriptan 50 mg for most patients with moderate to severe migraine 2. If inadequate response after 2 hours and some benefit was observed, a second dose may be given, separated by at least 2 hours, with a maximum of 200 mg in 24 hours 2.
For severe attacks with rapid escalation or significant nausea/vomiting, use subcutaneous sumatriptan 6 mg, which provides the fastest and most complete relief—approximately 60% of patients achieve pain freedom at 2 hours (NNT 2.3) compared to 15% with placebo 3. This route works within 15 minutes for cluster headache 4.
For moderate attacks without severe nausea, oral sumatriptan 100 mg provides pain freedom in 28% at 2 hours versus 11% with placebo (NNT 6.1), with headache relief NNT of 3.4 5, 6.
Step 2: Combination Therapy
Always combine sumatriptan with an NSAID or acetaminophen rather than using it as monotherapy 1. This combination approach is superior to either agent alone and should be initiated as early as possible when pain is still mild, which significantly improves efficacy 1, 6.
Step 3: Route Selection Based on Clinical Scenario
- Subcutaneous 6 mg: Most effective option (NNT 2.1 for headache relief), use for severe attacks or when rapid relief is critical 3
- Oral 100 mg: Standard dose for moderate-severe attacks (NNT 3.4 for headache relief) 6
- Oral 50 mg: Alternative for patients concerned about adverse events or first-time users 6
- Intranasal 20 mg: For patients with nausea who prefer to avoid injections (NNT 3.5) 3
- Oral 25 mg: Consider in patients with mild-moderate hepatic impairment (maximum 50 mg single dose in hepatic impairment) 2
Absolute Contraindications
Sumatriptan is contraindicated in 2:
- Coronary artery disease or coronary vasospasm
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathways
- History of stroke, TIA, hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Recent use (within 24 hours) of another triptan or ergotamine-containing medication
- Recent use (within 2 weeks) of MAO-A inhibitors
- Severe hepatic impairment
- Known hypersensitivity (angioedema/anaphylaxis)
Do not use during pregnancy or lactation without careful risk-benefit discussion 1, 2.
Common Adverse Effects
Adverse events occur more frequently than placebo (NNH 7.1 for oral 100 mg) but are typically transient and mild 5, 6:
- Most common (≥2%): Paresthesia, warm/cold sensations, chest pain/tightness/pressure/heaviness, neck/throat/jaw pain/tightness/pressure, vertigo, malaise/fatigue 2
- Subcutaneous route: Injection site reactions in ~30%, higher overall adverse event rate but most effective 3, 4
- Chest symptoms: Occur in 3-5% but rarely associated with true myocardial ischemia; however, perform cardiac evaluation in patients with multiple cardiovascular risk factors 2, 7
Critical Pitfalls to Avoid
Medication Overuse Headache
Limit sumatriptan use to ≤10 days per month to prevent medication overuse headache 1, 8. This threshold is lower than for NSAIDs (≥15 days/month). Patients exceeding this require detoxification and transition to preventive therapy 1.
Timing of Administration
Do not administer during the aura phase—wait until headache begins 4. However, once headache starts, treat as early as possible when pain is mild for superior outcomes 1, 6.
Headache Recurrence
Approximately 40% of initial responders experience headache recurrence within 24 hours 4, 6. This can be effectively treated with a second dose if the first dose provided some benefit, respecting the 2-hour minimum interval and 200 mg daily maximum 2.
Wrong Diagnosis
Only use if clear migraine diagnosis is established 2. If no response to the first treated attack, reconsider the diagnosis before treating subsequent attacks 2. Sumatriptan is not indicated for tension-type headache, migraine prevention, or cluster headache (though subcutaneous formulation is effective off-label for cluster) 2.
Drug Interactions
Never combine with ergotamine-containing medications or other triptans within 24 hours, or with MAO-A inhibitors within 2 weeks 2. Be vigilant for serotonin syndrome when used with SSRIs, SNRIs, or other serotonergic drugs 2.
When Sumatriptan Fails
If patients do not achieve adequate response to combination therapy of a triptan plus NSAID/acetaminophen, consider CGRP antagonists (gepants), dihydroergotamine, or lasmiditan as next-line options 1. Never use opioids or butalbital for acute migraine treatment 1.
If episodic migraine occurs frequently despite adequate acute treatment, add preventive medications 1.